Clinical Trial Update: Phase 1b/2 Study of Oprozomib in Combination With Sorafenib in Subjects With Advanced Hepatocellular Carcinoma [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1b/2 trial of oprozomib in combination with sorafenib for advanced hepatocellular carcinoma has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• Oprozomib (oprozomib)
• Sorafenib (Sorafenib)

Snippet

Sponsor: Amgen | Conditions: Advanced Hepatocellular Carcinoma | Phase 1, Phase 2 | Status: WITHDRAWN